0001415889-24-009073.txt : 20240325
0001415889-24-009073.hdr.sgml : 20240325
20240325204009
ACCESSION NUMBER: 0001415889-24-009073
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240321
FILED AS OF DATE: 20240325
DATE AS OF CHANGE: 20240325
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Scheiner Zachary
CENTRAL INDEX KEY: 0001816523
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40532
FILM NUMBER: 24780700
MAIL ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: 18TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LENZ Therapeutics, Inc.
CENTRAL INDEX KEY: 0001815776
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 844867570
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 445 MARINE VIEW AVE SUITE 320
CITY: DEL MAR
STATE: CA
ZIP: 92014
BUSINESS PHONE: 858-925-7000
MAIL ADDRESS:
STREET 1: 445 MARINE VIEW AVE SUITE 320
CITY: DEL MAR
STATE: CA
ZIP: 92014
FORMER COMPANY:
FORMER CONFORMED NAME: Graphite Bio, Inc.
DATE OF NAME CHANGE: 20210312
FORMER COMPANY:
FORMER CONFORMED NAME: Integral Medicines, Inc.
DATE OF NAME CHANGE: 20200622
4
1
form4-03262024_120359.xml
X0508
4
2024-03-21
0001815776
LENZ Therapeutics, Inc.
LENZ
0001816523
Scheiner Zachary
C/O RA CAPITAL MANAGEMENT
200 BERKELEY STREET, 18TH FLOOR
BOSTON
MA
02116
true
false
false
false
0
Stock Option (right to buy)
15.05
2024-03-21
4
A
0
27000
0
A
2034-03-20
Common Stock
27000
27000
D
Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 21, 2024.
Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus II Fund") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund, the Nexus II Fund and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.
/s/ Zachary Scheiner
2024-03-25